RECRUITING

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic pancreatic cancer and metastatic breast cancer. The investigational treatment will involve 2 cycles of a combination of intravenous melphalan, BCNU, vitamin B12b, and vitamin C with autologous hematopoietic stem cell infusion. A dose-escalation schedule is being employed for the vitamin C.

Official Title

SHARON: Study of Metastatic Cancers in Patients Using Autologous Stems Cells and Potentiated Redox Cycling to Overcome Drug Resistance to Nitrogen Mustard Derivatives

Quick Facts

Study Start:2021-01-13
Study Completion:2028-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04150042

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

General Oncology (study sponsor)
CONTACT
818-4-SHARON (818-474-2766)
contact@SharonTrial.com

Principal Investigator

Arnold Glazier, M.D.
STUDY_DIRECTOR
General Oncology, Inc.

Study Locations (Sites)

Massachusetts General Hospital
Boston, Massachusetts, 02114
United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
United States

Collaborators and Investigators

Sponsor: General Oncology, Inc.

  • Arnold Glazier, M.D., STUDY_DIRECTOR, General Oncology, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-01-13
Study Completion Date2028-12

Study Record Updates

Study Start Date2021-01-13
Study Completion Date2028-12

Terms related to this study

Keywords Provided by Researchers

  • pancreatic adenocarcinoma
  • pancreatic cancer
  • BRCA
  • BRCA1
  • BRCA2
  • melphalan
  • BCNU
  • carmustine
  • vitamin C
  • vitamin B12b
  • autologous stem cell infusion
  • stage 4 pancreatic cancer
  • metastatic pancreatic cancer
  • pancreatic acinar cell carcinoma
  • pancreatic ductal adenocarcinoma
  • PDAC
  • breast cancer
  • stage 4 breast cancer
  • stage IV pancreatic cancer
  • stage IV breast cancer
  • stem cells
  • HER2-negative breast cancer
  • PALB2
  • metastatic breast cancer
  • BRCA pancreatic cancer
  • BRCA breast cancer

Additional Relevant MeSH Terms

  • Pancreatic Adenocarcinoma Metastatic
  • BRCA1 Mutation
  • BRCA2 Mutation
  • Pancreatic Acinar Cell Carcinoma
  • Pancreatic Ductal Adenocarcinoma
  • Pancreatic Cancer
  • Metastatic Pancreatic Cancer
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Breast Cancer Metastatic
  • Breast Cancer Stage IV
  • Pancreatic Cancer Stage IV
  • HER2-negative Breast Cancer
  • HER2 Negative Breast Carcinoma
  • Adenocarcinoma of the Breast
  • PALB2 Gene Mutation
  • Pancreas Cancer, Metastatic
  • Pancreas Cancer, Recurrent
  • Pancreas Cancer
  • Stage IV Pancreatic Cancer
  • Stage 4 Pancreatic Cancer